Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Oral AN2-502998 in Healthy Adults
NCT07024589Phase 1Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Reversible Covalent Inhibitors, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AN2-502998 (2 arms), sponsored by AN2 Therapeutics, Inc. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Physical Examination Abnormalities and 8 more. Started Aug 2025; status: completed.
02
Drugs
AN2-502998
Beyond the preview
Go deeper on NCT07024589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024589.